Skip to main
KMTS

KMTS Stock Forecast & Price Target

KMTS Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Kestra Medical Techs is well-positioned for future success in the MedTech industry, with a strong product offering and solid financials. Their focus on expanding into new markets and increasing profitability make them attractive to investors. With a strong team and a competitive product, Kestra has the potential for continued growth and market share expansion. Their recent IPO and consistent funding also indicate confidence in the company's future prospects.

Bears say

Kestra Medical Techs is attempting to disrupt the wearable medical device and digital healthcare market with their innovative Cardiac Recovery System platform. However, as a commercial-stage company, Kestra still has a long way to go in terms of gaining market share, increasing conversion rates, and expanding into new geographies. Additionally, with a low gross margin compared to its peers and high operating expenses, it may take some time for the company to reach profitability. Furthermore, there is still uncertainty surrounding the effectiveness and safety of the device, as reflected in lower utilization and higher inappropriate shock rates compared to its competitor, Zoll Medical's LifeVest.

KMTS has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kestra Medical Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kestra Medical Technologies Inc (KMTS) Forecast

Analysts have given KMTS a Buy based on their latest research and market trends.

According to 4 analysts, KMTS has a Buy consensus rating as of Apr 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kestra Medical Technologies Inc (KMTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.